Skip to main content

Advertisement

Table 1 Demographics and baseline characteristics of the study population (FAS Year 5 , N = 377)

From: Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score

Parameter Treatment group  
Placebo n = 133 300IR (2 M) n = 117 300IR (4 M) n = 127 Total N = 377
Gender, n (%)     
 Male 79 (59.4) 71 (60.7) 81 (63.8) 231 (61.3)
 Female 54 (40.6) 46 (39.3) 46 (36.2) 146 (38.7)
Age, years     
 n 133 117 127 377
 Mean (SD) 30.1 (8.7) 30.9 (7.8) 30.5 (8.5) 30.5 (8.3)
 Range 18–49 18–51 18–49 18–51
Body mass index, kg/m 2     
 n 132 117 127 376
 Mean (SD) 23.9 (4.3) 24.3 (3.9) 24.2 (3.7) 24.1 (4.0)
 Range 15.6–42.4 17.3–35.1 17.2–35.1 15.6–42.4
Duration of ARC, years     
 n 133 117 127 377
 Mean (SD) 12.5 (9.0) 12.9 (8.8) 13.0 (9.2) 12.8 (9.0)
 Range 1.6–44.0 1.5–39.0 1.5–42.1 1.5–44.0
RRTSS     
 n 133 117 127 377
 Mean (SD) 14.0 (1.7) 13.9 (1.8) 14.2 (1.7) 14.1 (1.7)
 Range 12–18 12–18 12–18 12–18
Asthma status, n (%)     
 Yes 19 (14.3) 13 (11.1) 16 (12.6) 48 (12.7)
 No 114 (85.7) 104 (88.9) 111 (87.4) 329 (87.3)
Sensitization status, n (%)     
 Monosensitized 53 (39.8) 47 (40.2) 53 (41.7) 153 (40.6)
 Polysensitized 80 (60.2) 70 (59.8) 74 (58.3) 224 (59.4)
  1. 2 M, 2-month preseasonal dosing protocol; 4 M, 4-month preseasonal dosing protocol; ARC, allergic rhinoconjunctivitis; FAS, full analysis set; IR, index of reactivity; RRTSS, retrospective rhinoconjunctivitis total symptom score; SD, standard deviation.